Drugs / Cisplatin
last change yesterday re-read 8 days ago

Cisplatin

Other / unclassified

Developed for
non-small cell lung carcinoma · head and neck squamous cell carcinoma · head and neck cancer · gastric cancer · nasopharyngeal carcinoma · esophageal cancer · cervical cancer · lung cancer
+429 more · esophageal squamous cell carcinoma · small cell lung carcinoma · urinary bladder cancer · breast cancer · biliary tract cancer · oropharynx squamous cell carcinoma · cancer · ovarian cancer · ovarian carcinoma · urothelial carcinoma · intrahepatic cholangiocarcinoma · malignant pleural mesothelioma · malignant pancreatic neoplasm · neuroblastoma · triple-negative breast carcinoma · cancer of unknown primary site · cholangiocarcinoma · lymphoma · peritoneal carcinomatosis · pancreatic adenocarcinoma · primary peritoneal carcinoma · squamous cell carcinoma · pancreatic ductal adenocarcinoma · gastric adenocarcinoma · gastroesophageal junction adenocarcinoma · hepatocellular carcinoma · renal pelvis/ureter urothelial carcinoma · central nervous system neoplasm · cervical carcinoma · oral cavity squamous cell carcinoma · hypopharynx squamous cell carcinoma · sarcoma · endometrial cancer · fallopian tube cancer · infiltrating bladder urothelial carcinoma · gastric neoplasm · malignant mesothelioma · plasma cell myeloma · urethra cancer · colorectal cancer · neoplasm · laryngeal squamous cell carcinoma · metastatic neoplasm · oral cavity cancer · urinary bladder carcinoma · extragonadal germ cell tumor · fallopian tube carcinoma · gallbladder cancer · head and neck neoplasm · lung adenocarcinoma · melanoma · metastatic malignant neoplasm · bladder transitional cell carcinoma · brain cancer · cutaneous melanoma · esophageal adenocarcinoma · female breast carcinoma · gallbladder carcinoma · hypopharyngeal carcinoma · lung neoplasm · malignant epithelial tumor of ovary · oropharynx cancer · adrenal cortex carcinoma · carcinoma of esophagus · endometrial clear cell adenocarcinoma · endometrial serous adenocarcinoma · gastroesophageal cancer · liver cancer · osteosarcoma · peritoneum cancer · soft tissue sarcoma · testicular germ cell tumor · cervical adenosquamous carcinoma · gastric carcinoma · germ cell tumor · medulloblastoma · metastatic malignant neoplasm in the brain · neoplasm of esophagus · neuroendocrine carcinoma · oropharyngeal carcinoma · peripheral T-cell lymphoma, not otherwise specified · childhood germ cell tumor · human papillomavirus-related squamous cell carcinoma · larynx cancer · mesothelioma · nasal cavity and paranasal sinus squamous cell carcinoma · pleural neoplasm · squamous cell lung carcinoma · teratoma · thymoma · anal carcinoma · biliary tract neoplasm · cervical squamous cell carcinoma · diffuse large B-cell lymphoma · digestive system carcinoma · extranodal nasal NK/T cell lymphoma · hepatoblastoma · hypopharynx cancer · nasopharyngeal squamous cell carcinoma · ovarian endometrioid adenocarcinoma · ovarian neoplasm · peritoneal carcinoma · peritoneal neoplasm · transitional cell carcinoma · ureter cancer · verrucous carcinoma of oral cavity · adenocarcinoma · breast mucinous carcinoma · colorectal neoplasm · digestive system neoplasm · glioma · laryngeal carcinoma · larynx verrucous carcinoma · lung carcinoma · malignant peritoneal mesothelioma · nasopharyngeal neoplasm · non-Hodgkin lymphoma · oral cavity neoplasm · ovarian serous adenocarcinoma · penile cancer · penile carcinoma · prostate cancer · tongue cancer · tongue carcinoma · undifferentiated ovarian carcinoma · vulva cancer · BRCA1-related cancer predisposition · breast carcinoma · carcinoma · central nervous system germ cell tumor · childhood medulloblastoma · classic Hodgkin lymphoma · combined thymoma · cutaneous neuroendocrine carcinoma · digestive system cancer · distal biliary tract carcinoma · endometrial adenosquamous carcinoma · extrahepatic bile duct carcinoma · fallopian tube endometrioid adenocarcinoma · fallopian tube mucinous adenocarcinoma · gastroesophageal adenocarcinoma · Hodgkins lymphoma · inflammatory breast carcinoma · invasive tubular breast carcinoma · lip and oral cavity squamous cell carcinoma · lung large cell carcinoma · malignant tumor of neck · mantle cell lymphoma · metastatic malignant neoplasm in the lymph nodes · metastatic melanoma · neuroendocrine neoplasm · ovarian clear cell adenocarcinoma · ovarian mucinous adenocarcinoma · pancreas disorder · pancreatic exocrine neoplasm · pancreatic neoplasm · primary peritoneal serous adenocarcinoma · rhabdomyosarcoma · salivary gland squamous cell carcinoma · seminoma · skin cancer · T-cell non-Hodgkin lymphoma · testicular cancer · testicular seminoma · thymic carcinoma · vulvar squamous cell carcinoma · adenosquamous lung carcinoma · ALK-negative anaplastic large cell lymphoma · anal squamous cell carcinoma · angioimmunoblastic T-cell lymphoma · anus cancer · atypical teratoid rhabdoid tumor · bile duct carcinoma · bladder squamous cell carcinoma · bone sarcoma · breast neoplasm · carcinoid tumor · central nervous system cancer · colon carcinoma · colorectal adenocarcinoma · desmoplastic small round cell tumor · diffuse gastric adenocarcinoma · endometrial carcinoma · endometrial endometrioid adenocarcinoma · endometrial undifferentiated carcinoma · endometrium neoplasm · enteropathy-associated T-cell lymphoma · esophageal small cell neuroendocrine carcinoma · fallopian tube clear cell adenocarcinoma · fallopian tube serous adenocarcinoma · fallopian tube transitional cell carcinoma · female reproductive organ cancer · gastric intestinal type adenocarcinoma · head and neck carcinoma · hepatosplenic T-cell lymphoma · Her2-receptor negative breast cancer · hereditary breast carcinoma · hilar cholangiocarcinoma · Hodgkin's lymphoma, lymphocytic depletion · Hodgkin's lymphoma, mixed cellularity · invasive breast carcinoma · mature T-cell and NK-cell non-Hodgkin lymphoma · metastatic prostate carcinoma · metastatic squamous cell carcinoma · nasal cavity and paranasal sinus carcinoma · nasal cavity and paranasal sinus neoplasm · neoplastic disease or syndrome · nodular sclerosis classical Hodgkin lymphoma · non-small cell squamous lung carcinoma · ovarian Brenner tumor · ovarian carcinosarcoma · ovarian clear cell cystadenocarcinoma · ovarian embryonal carcinoma · ovarian mucinous cystadenocarcinoma · ovarian serous cystadenocarcinoma · ovarian transitional cell carcinoma · ovarian yolk sac tumor · pediatric hepatocellular carcinoma · pineoblastoma · pleural epithelioid mesothelioma · refractory malignant neoplasm · renal cell carcinoma · salivary gland cancer · salivary gland carcinoma · sinonasal undifferentiated carcinoma · small cell carcinoma · small intestine cancer · testicular embryonal carcinoma · ureter transitional cell carcinoma · urinary bladder neoplasm · urinary bladder small cell neuroendocrine carcinoma · uterine cancer · uterine cervix neoplasm · uterine corpus cancer · acute myeloid leukemia, KRAS gene mutation · adenoid cystic carcinoma · adult hepatocellular carcinoma · adult medulloblastoma · adult T-cell leukemia/lymphoma · anal canal cancer · anal canal carcinoma · anal canal squamous cell carcinoma · anaplastic ependymoma · anaplastic large cell lymphoma · anterior urethra cancer · anus basaloid carcinoma · B-cell non-Hodgkin lymphoma · basal cell carcinoma · basaloid squamous cell carcinoma · bile duct adenocarcinoma · bladder mixed adenocarcinoma · bladder urachal carcinoma · bone cancer · bone osteosarcoma · bone squamous cell carcinoma · brain glioblastoma · Brenner tumor · carcinoma of the ampulla of vater · castration-resistant prostate carcinoma · cellular ependymoma · cervical adenocarcinoma · childhood ependymoma · childhood malignant neoplasm · childhood testicular germ cell tumor · choriocarcinoma · choriocarcinoma of ovary · choriocarcinoma of testis · choroid plexus neoplasm · clear cell ependymoma · cloacogenic carcinoma · combined hepatocellular carcinoma and cholangiocarcinoma · diffuse gastric cancer · digestive system neuroendocrine neoplasm · embryonal tumor with multilayered rosettes · endocervical adenocarcinoma · endocrine gland neoplasm · endometrial mixed adenocarcinoma · endometrial mucinous adenocarcinoma · endometrial squamous cell carcinoma · ependymoblastoma · esophageal disorder · Ewing sarcoma · extragonadal nonseminomatous germ cell tumor · extragonadal seminoma · extramammary Paget disease · extramedullary plasmacytoma · extraocular retinoblastoma · fallopian tube adenocarcinoma · fallopian tube carcinosarcoma · fibrolamellar hepatocellular carcinoma · ganglioneuroblastoma · gastrointestinal stromal tumor · germinoma · gestational trophoblastic neoplasm · glioblastoma · hemophagocytic syndrome · high grade B-cell lymphoma · high grade malignant neoplasm · HIV-associated cancer · hormone-resistant prostate carcinoma · infiltrating bladder urothelial carcinoma sarcomatoid variant · infiltrating bladder urothelial carcinoma, clear cell variant · intestinal obstruction · intrahepatic bile duct cancer · intraocular retinoblastoma · leukemia · light chain deposition disease · lip and oral cavity carcinoma · lip cancer · liposarcoma · liver disorder · lung disorder · lymphoepithelial-like carcinoma · major salivary gland cancer · malignant biphasic mesothelioma · malignant glioma · malignant neoplasm of thoracic esophagus · malignant ovarian Brenner tumor · malignant teratoma · malignant testicular germ cell tumor · malignant tumor of meninges · maxillary sinus squamous cell carcinoma · mediastinal cancer · medulloblastoma non-WNT/non-SHH group 3 · medulloblastoma non-WNT/non-SHH group 4 · medulloblastoma SHH activated and TP53 wild-type · medulloepithelioma · metastatic carcinoma · metastatic carcinoma in the bone · micropapillary variant infiltrating bladder urothelial carcinoma · mixed germ cell tumor · mixed testicular germ cell cancer · myeloproliferative neoplasm · nasal cavity adenocarcinoma · nasal cavity cancer · nasal cavity squamous cell carcinoma · nasopharyngeal type undifferentiated carcinoma · neoplasm of neck · neoplasm of oropharynx · neoplasm of testis · neoplasm of thorax · nested variant infiltrating bladder urothelial carcinoma · nodular lymphocyte predominant Hodgkin lymphoma · non-central nervous system-localized embryonal carcinoma · nongerminomatous germ cell tumor · nut midline carcinoma · ocular melanoma · olfactory neuroblastoma · ovarian adenocarcinoma · ovarian epithelial tumor · ovarian granulosa cell tumor · ovarian gynandroblastoma · ovarian seromucinous carcinoma · ovarian seromucinous tumor · ovarian Sertoli-Leydig cell tumor · ovarian sex cord-stromal tumor · pancreatic acinar cell carcinoma · pancreatic adenosquamous carcinoma · pancreatic neuroendocrine tumor · papillary ependymoma · papillary squamous carcinoma · paranasal sinus cancer · paranasal sinus carcinoma · paranasal sinus neoplasm · pediatric ovarian germ cell tumor · periampullary adenocarcinoma · pharynx cancer · pharynx neoplasm · pheochromocytoma · plasma cell leukemia · plasmacytoid variant infiltrating bladder urothelial carcinoma · pleural mesothelioma · poorly differentiated thyroid gland carcinoma · posterior urethra cancer · primary brain neoplasm · primary systemic amyloidosis · primitive neuroectodermal tumor · prostate carcinoma · prostate small cell carcinoma · pulmonary large cell neuroendocrine carcinoma · rectal carcinoma · renal pelvis carcinoma · renal pelvis neoplasm · salivary gland adenoid cystic carcinoma · sarcomatoid mesothelioma · secondary malignant neoplasm · serous adenocarcinoma · skull base neoplasm · solitary osseous plasmacytoma · squamous cell carcinoma of penis · squamous cell carcinoma of the oral tongue · subcutaneous panniculitis-like T-cell lymphoma · supratentorial primitive neuroectodermal tumor · testicular non-seminomatous germ cell tumor · testicular yolk sac tumor · thymic epithelial neoplasm · thymus cancer · thyroid gland carcinoma · thyroid gland undifferentiated (anaplastic) carcinoma · tonsil cancer · tumor of salivary gland · tumor of uterus · undifferentiated carcinoma of nasopharynx · upper aerodigestive tract neoplasm · urachus cancer · ureter neoplasm · ureter small cell carcinoma · urethra neoplasm · urethra transitional cell carcinoma · uterine adnexa cancer · uterine corpus sarcoma · vaginal cancer · vaginal carcinoma · vulval Paget disease · vulvar carcinoma · Waldenstrom macroglobulinemia · Wilms tumor · yolk sac tumor · aggressive B-cell non-Hodgkin lymphoma · bile duct cancer · colon adenocarcinoma · gastric neuroendocrine neoplasm · hydatidiform mole · intestinal neuroendocrine neoplasm · malignant germ cell tumor of ovary · non-invasive bladder urothelial carcinoma · pancreatic neuroendocrine neoplasm · rectum adenocarcinoma · RET fusion positive cancer
Investigated by
National Cancer Institute (NCI) · Sun Yat-sen University · Eli Lilly and Company · Memorial Sloan Kettering Cancer Center · Fudan University · AstraZeneca
+1,159 more · Merck Sharp & Dohme LLC · M.D. Anderson Cancer Center · European Organisation for Research and Treatment of Cancer - EORTC · Sanofi · Dana-Farber Cancer Institute · SWOG Cancer Research Network · Radiation Therapy Oncology Group · Gynecologic Oncology Group · Eastern Cooperative Oncology Group · Bristol-Myers Squibb · Tianjin Medical University Cancer Institute and Hospital · Brigham and Women's Hospital · Children's Oncology Group · Alliance for Clinical Trials in Oncology · NRG Oncology · Chinese Academy of Medical Sciences · Mayo Clinic · Pfizer · UNICANCER · Genentech, Inc. · Massachusetts General Hospital · National Taiwan University Hospital · Zhejiang Cancer Hospital · Samsung Medical Center · Cancer Research UK · Hoffmann-La Roche · NCIC Clinical Trials Group · Asan Medical Center · Fujian Cancer Hospital · University of Chicago · Washington University School of Medicine · Yonsei University · Celgene Corporation · Children's Cancer and Leukaemia Group · Jiangsu HengRui Medicine Co., Ltd. · Medical Research Council · Peking University Cancer Hospital & Institute · Swiss Cancer Institute · University Health Network, Toronto · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Henan Cancer Hospital · RenJi Hospital · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Cancer and Leukemia Group B · Gustave Roussy, Cancer Campus, Grand Paris · Hebei Medical University Fourth Hospital · Hunan Cancer Hospital · NYU Langone Health · Peking University · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · City of Hope Medical Center · ECOG-ACRIN Cancer Research Group · GlaxoSmithKline · Qilu Hospital of Shandong University · Roche Pharma AG · Ruijin Hospital · Shanghai Jiao Tong University School of Medicine · Tongji Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · West China Hospital · Women's Hospital School Of Medicine Zhejiang University · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Case Comprehensive Cancer Center · Emory University · Fox Chase Cancer Center · GERCOR - Multidisciplinary Oncology Cooperative Group · Guangdong Provincial People's Hospital · HonorHealth Research Institute · Jiangsu Cancer Institute & Hospital · Merck KGaA, Darmstadt, Germany · Ministry of Health, Labour and Welfare, Japan · National Cancer Center, Korea · Shandong Cancer Hospital and Institute · The Netherlands Cancer Institute · all 1,165 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) PLATINOL-AQ — 1981-12-29 – 1993-04-22 fda.gov ↗
Approved US (FDA) PLATINOL-AQ — 1978-12-19 fda.gov ↗

Trials 2,269 · started per year

today
US approved 1978
1
3
5
6
8
15
17
21
42
39
61
47
51
62
81
54
73
72
84
86
88
63
66
55
61
65
81
77
79
64
65
83
89
81
94
130
107
78
3
19781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 019 trials
Phase 0 NCT06942039 Sep 2025 → Dec 2030 expected atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 C17 Council Recruiting No outcome recorded
Phase 0 NCT07028918 Aug 2025 → Aug 2026 overdue oral cavity squamous cell carcinoma Qilu Hospital of Shandong University Not yet recruiting No outcome recorded
Phase 0 NCT07034742 Jun 2025 → Jan 2026 overdue gastric adenocarcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 0 NCT06690476 Oct 2024 → Jul 2026 overdue esophageal squamous cell carcinoma Peking University Recruiting No outcome recorded
Phase 0 NCT06525714 Aug 2024 → Jul 2029 expected gastric cancer The First Hospital of Jilin University Not yet recruiting No outcome recorded
Phase 0 NCT06204614 Jun 2024 → Jul 2028 expected infiltrating bladder urothelial carcinoma Brigham and Women's Hospital Enrolling by invitation No outcome recorded
Phase 0 NCT06208033 Jan → Oct 2024 non-small cell lung carcinoma Fujian Cancer Hospital Unknown No outcome recorded
Phase 0 NCT05553782 Nov 2023 → Apr 2029 expected head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma Brigham and Women's Hospital Recruiting No outcome recorded
Phase 0 NCT05415709 Jun 2022 → Dec 2026 expected fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma +3 Ohio State University Comprehensive Cancer Center Recruiting No outcome recorded
Phase 0 NCT04265872 Oct 2020 → Dec 2026 expected breast cancer Baylor Research Institute Recruiting No outcome recorded
Phase 1241 trials · 1 met primary
Phase 1 NCT05403723 Jan 2027 → Feb 2028 small cell lung carcinoma University of Maryland, Baltimore Suspended No outcome recorded
Phase 1 NCT07495098 Jul 2026 → Jul 2030 expected non-small cell lung carcinoma University of Vermont Not yet recruiting No outcome recorded
Phase 1 NCT06724042 Jun 2026 → Jun 2029 expected metastatic neoplasm, neoplasm InSilico Medicine Not yet recruiting No outcome recorded
Phase 1 NCT07353294 Jan 2026 → Dec 2028 expected metastatic malignant neoplasm in the lymph nodes, urothelial carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Enrolling by invitation No outcome recorded
Phase 1 NCT07090499 Aug 2025 → Jul 2028 expected esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma +4 Pfizer Recruiting No outcome recorded
Phase 1 NCT07046923 Jul 2025 → Jul 2030 expected endometrium neoplasm, metastatic neoplasm, non-small cell lung carcinoma, small cell lung carcinoma +1 Eli Lilly and Company Recruiting No outcome recorded
Phase 1 NCT06657144 Apr 2025 → Jan 2028 expected metastatic neoplasm Coherus Oncology, Inc. Recruiting No outcome recorded
Phase 1 NCT06917079 Mar 2025 → Aug 2027 expected colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Recruiting No outcome recorded
Phase 1 NCT06835569 Mar 2025 → May 2029 expected colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma Alterome Therapeutics, Inc. Recruiting No outcome recorded
Phase 1 NCT06076837 Jan → Dec 2025 pancreatic adenocarcinoma HonorHealth Research Institute Terminated No outcome recorded
Show all 241 trials opens the full record — a long page
Phase 1/2167 trials · 2 met primary · 2 missed
Phase 1/2 NCT07559929 Aug 2026 → Jun 2028 expected small cell lung carcinoma Hangzhou DAC Biotechnology Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07453394 Apr 2026 → Apr 2027 expected endometrial cancer, gastric cancer, non-small cell lung carcinoma, ovarian cancer Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07466160 Feb 2026 → Dec 2027 expected cancer Mabwell (Shanghai) Bioscience Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07397338 Jan 2026 → May 2029 expected colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma Revolution Medicines, Inc. Recruiting No outcome recorded
Phase 1/2 NCT07272590 Dec 2025 → Jun 2027 expected metastatic neoplasm Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07258979 Nov 2025 → Feb 2028 expected nasopharyngeal carcinoma MediLink Therapeutics (Suzhou) Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07256782 Oct 2025 → Oct 2026 expected neoplastic disease or syndrome Qilu Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06405230 Oct 2025 → Jul 2026 non-small cell lung carcinoma GlaxoSmithKline Terminated No outcome recorded
Phase 1/2 NCT06543576 Jul 2025 → Jan 2031 expected cervical adenosquamous carcinoma Jonsson Comprehensive Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT07121374 Jul 2025 → Jun 2028 expected pleural epithelioid mesothelioma University Hospital, Antwerp Recruiting No outcome recorded
Show all 167 trials opens the full record — a long page
Phase 21,305 trials · 28 met primary · 63 missed
Phase 2 NCT07639528 Dec 2027 → Dec 2030 expected intrahepatic cholangiocarcinoma Northwestern University Not yet recruiting No outcome recorded
Phase 2 NCT04595981 May 2027 → May 2029 head and neck squamous cell carcinoma University of Alabama at Birmingham Withdrawn No outcome recorded Stop: Business
Phase 2 NCT07780838 Nov 2026 → Dec 2027 expected carcinoma of the ampulla of vater, distal biliary tract carcinoma, gallbladder carcinoma, intrahepatic cholangiocarcinoma Ohio State University Comprehensive Cancer Center Recruiting No outcome recorded
Phase 2 NCT07843303 Oct 2026 → Sep 2028 expected fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2 NCT07845916 Oct 2026 → Jun 2027 expected non-small cell lung carcinoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Not yet recruiting No outcome recorded
Phase 2 NCT07811375 Oct 2026 → Mar 2029 expected cervical cancer Anhui Provincial Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07856069 Oct 2026 → Oct 2030 expected medulloblastoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting No outcome recorded
Phase 2 NCT06855225 Oct 2026 → May 2027 expected combined hepatocellular carcinoma and cholangiocarcinoma Mehmet Akce Not yet recruiting No outcome recorded
Phase 2 NCT07828756 Sep 2026 → Oct 2027 expected malignant pancreatic neoplasm Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07751341 Sep 2026 → Dec 2027 expected esophageal squamous cell carcinoma Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting No outcome recorded
Show all 1,305 trials opens the full record — a long page
Phase 2/350 trials · 2 met primary · 5 missed
Phase 2/3 NCT07463313 Mar 2026 → Mar 2029 expected combined thymoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 2/3 NCT07005102 Aug 2025 → Nov 2036 expected non-small cell lung carcinoma AbbVie Recruiting No outcome recorded
Phase 2/3 NCT06783140 Jun 2025 → Jun 2031 expected PALB2-related cancer predisposition, malignant pancreatic neoplasm University Health Network, Toronto Active not recruiting No outcome recorded
Phase 2/3 NCT06923475 May 2025 → Nov 2028 expected distal biliary tract carcinoma, hilar cholangiocarcinoma Amsterdam UMC, location VUmc Not yet recruiting No outcome recorded
Phase 2/3 NCT06866951 Mar 2025 → Dec 2028 cervical cancer Women's Hospital School Of Medicine Zhejiang University Withdrawn No outcome recorded Stop: Enrollment
Phase 2/3 NCT06115499 Aug 2024 → Jan 2029 expected pancreatic acinar cell carcinoma, pancreatic adenosquamous carcinoma, pancreatic ductal adenocarcinoma Alliance for Clinical Trials in Oncology Active not recruiting No outcome recorded
Phase 2/3 NCT06268327 Apr 2024 → Oct 2025 overdue breast cancer Assiut University Not yet recruiting No outcome recorded
Phase 2/3 NCT06095141 Dec 2023 → Oct 2025 overdue pancreatic ductal adenocarcinoma Fudan University Recruiting No outcome recorded
Phase 2/3 NCT06037980 Nov 2023 → Dec 2028 expected cholangiocarcinoma Gruppo Oncologico del Nord-Ovest Recruiting No outcome recorded
Phase 2/3 NCT06138028 Sep 2023 → Oct 2025 overdue esophageal squamous cell carcinoma Qingdao Central Hospital Recruiting No outcome recorded
Phase 3391 trials · 51 met primary · 66 missed
Phase 3 NCT07715396 Oct 2026 → Oct 2031 expected non-small cell lung carcinoma AIO-Studien-gGmbH Not yet recruiting No outcome recorded
Phase 3 NCT07291102 Jul 2026 → Oct 2034 expected medulloblastoma SHH activated and TP53 wild-type Nationwide Children's Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07371897 Jun 2026 overdue head and neck squamous cell carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT07540390 May 2026 → Dec 2032 expected nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT07554846 May 2026 → May 2030 expected — Fudan University Recruiting No outcome recorded
Phase 3 NCT07400536 Apr 2026 → Jul 2028 expected cervical carcinoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting No outcome recorded
Phase 3 NCT07524413 Apr 2026 → Apr 2030 expected nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT07402538 Feb 2026 → Dec 2028 expected oral cavity cancer, oropharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT06952621 Feb 2026 → Dec 2027 expected esophageal squamous cell carcinoma Tang-Du Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07371611 Jan 2026 → Dec 2030 expected oral cavity squamous cell carcinoma Qunxing Li,MD Recruiting No outcome recorded
Show all 391 trials opens the full record — a long page
Phase 433 trials · 2 met primary
Phase 4 NCT07801027 Nov 2026 → Jan 2030 expected biliary tract cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, uterine cervix neoplasm Merck Sharp & Dohme LLC Not yet recruiting No outcome recorded
Phase 4 NCT07619235 Jun 2026 → Jul 2028 expected biliary tract cancer Xianglin Yuan Recruiting No outcome recorded
Phase 4 NCT07279935 May 2026 → May 2030 expected non-small cell lung carcinoma AstraZeneca Recruiting No outcome recorded
Phase 4 NCT06951841 Apr 2025 → May 2026 overdue small cell lung carcinoma China Medical University, China Not yet recruiting No outcome recorded
Phase 4 NCT06485739 Jul 2024 → Jul 2028 expected neuroendocrine neoplasm First Affiliated Hospital Xi'an Jiaotong University Not yet recruiting No outcome recorded
Phase 4 NCT06357598 Jan → Dec 2024 non-small cell lung carcinoma The Affiliated Hospital of Qingdao University Unknown No outcome recorded
Phase 4 NCT05444673 Jun 2022 → Jun 2023 bone squamous cell carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Unknown No outcome recorded
Phase 4 NCT04999878 May 2021 → Jun 2023 hemophagocytic syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma Zhengzhou University Unknown No outcome recorded
Phase 4 NCT04480268 Jul 2020 → Jan 2022 pancreatic ductal adenocarcinoma IRCCS San Raffaele Unknown No outcome recorded
Phase 4 NCT03691441 Jan 2018 → May 2024 oropharynx cancer University Medical Center Hamburg-Eppendorf Unknown No outcome recorded
Phase not applicable61 trials · 1 missed
— NCT07546383 Apr 2026 → Dec 2027 expected head and neck squamous cell carcinoma The Second Affiliated Hospital of Hainan Medical University Recruiting No outcome recorded
— NCT07388095 Feb 2026 → Feb 2027 expected esophageal squamous cell carcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
— NCT06434493 Nov 2024 → Jun 2028 expected cholangiocarcinoma The Christie NHS Foundation Trust Not yet recruiting No outcome recorded
— NCT06611345 Oct 2024 → Oct 2026 expected biliary tract cancer Jiangsu Healthy Life Innovation Medical Technology Co., Ltd Recruiting No outcome recorded
— NCT06558682 Oct 2024 → Oct 2026 expected cervical cancer Qilu Hospital of Shandong University Recruiting No outcome recorded
— NCT06420908 May 2024 → May 2026 esophageal squamous cell carcinoma Hebei Medical University Fourth Hospital Withdrawn No outcome recorded Stop: Enrollment
— NCT06262386 Aug 2023 → Jul 2028 expected lung cancer Chang Gung Memorial Hospital Recruiting No outcome recorded
— NCT05705687 May 2023 → Feb 2031 expected nongerminomatous germ cell tumor Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
— NCT06902467 Feb 2023 → Mar 2026 overdue ovarian cancer Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia Recruiting No outcome recorded
— NCT05644249 Dec 2022 → Jun 2025 gastric cancer, peritoneal carcinomatosis Vilnius University Completed No outcome recorded
Phase not stated2 trials
— NCT02985658 — hereditary breast carcinoma, triple-negative breast carcinoma University of Washington No longer available No outcome recorded
— NCT00040625 — mesothelioma Eli Lilly and Company Approved for marketing No outcome recorded
Comparator or background therapy1,882 trials
Phase 0 NCT07821177 Background Sep 2026 → Sep 2027 expected urinary bladder carcinoma, urothelial carcinoma Dana-Farber Cancer Institute Active not recruiting No outcome recorded
Phase 0 NCT07295262 Background Jan 2026 → Jul 2028 expected adult hepatocellular carcinoma West China Hospital Recruiting No outcome recorded
Phase 0 NCT07168785 Background Oct 2025 → Jun 2027 expected head and neck squamous cell carcinoma Indiana University Not yet recruiting No outcome recorded
Phase 0 NCT04161248 Background Sep 2020 → Dec 2026 expected B-cell non-Hodgkin lymphoma Canadian Cancer Trials Group Active not recruiting No outcome recorded
Phase 0 NCT02550327 Background Jan 2016 → Jun 2021 pancreatic adenocarcinoma Baylor Research Institute Completed No outcome recorded
Show all 1,882 trials opens the full record — a long page

Press releases naming this drug 77 releases

DateIssuerRelease
2026-07-12 Astellas Pharma Inc U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility astellas.com ↗
2026-07-10 Pfizer U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗
2026-06-24 Merck Sharp & Dohme LLC European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer merck.com ↗
2026-06-23 Astellas Pharma Inc European Commission Approves PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) as the First and Only Approved Perioperative Treatment Option for Cisplatin-Ineligible Patients with Resectable Muscle-Invasive Bladder Cancer astellas.com ↗
2026-05-22 Merck Sharp & Dohme LLC Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer merck.com ↗
2026-05-21 Astellas Pharma Inc PADCEV™ (enfortumab vedotin) in Combination with Keytruda® (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Patients with Resectable Muscle-Invasive Bladder Cancer who are Ineligible for Cisplatin-Based Chemotherapy astellas.com ↗
2026-05-14 Astellas Pharma Inc Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer astellas.com ↗
2026-04-20 Pfizer U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗
2026-04-20 Merck Sharp & Dohme LLC FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer merck.com ↗
2026-04-20 Astellas Pharma Inc U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility astellas.com ↗
2026-03-22 Astellas Pharma Inc EMA Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) plus Keytruda ® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer astellas.com ↗
2026-03-01 Astellas Pharma Inc PADCEV™ + Keytruda ® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer astellas.com ↗

Evidence & citations 47 cited values

Every value below carries the sentence it was read from. 4,163 sources stand behind the page.

FieldValueCited text
Known as Cisplatin “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗
4093

“Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone,...” NCT00577096 ↗

“Patients presented with non-keratinizing NPC and stage AnyTN2-3M0 and plasma EBV DNA≥1500copies/ml are randomly assigned to receive TPF(paclitaxel...” NCT03306121 ↗

“One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗

“The liquid chemotherapeutic drugs (Cisplatin 10.5 mg/m2 body surface in a total of 150 mL NaCl 0.9 %; Doxorubicin 2.1 mg/m2 body surface in a total of 50 mL NaCl 0.9 %) are...” NCT05303714 ↗

“Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks...” NCT04833257 ↗

“Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential...” NCT06727617 ↗

“After the start of External Beam Radiation Therapy (EBRT), paclitaxel (150-175 mg/m2) or paclitaxel (albumin-bound) 222-260 mg/m2 + cisplatin (60-75 mg/m2) or carboplatin...” NCT06870565 ↗

“Fluorouracil, 1000 mg/m2 per day, intravenously for days 1 to 4; cisplatin, 70 mg/m2 (or carboplatin, area under the curve, 5) intravenously on day 1; and pembrolizumab, 200...” PMID 40965911 ↗ Nov 2025

“Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed...” NCT04951648 ↗

“Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by...” NCT07608159 ↗

Show 4,083 more sources

Known as Abiplatin “Abiplatin” NCT04106362 ↗
Known as CACP “CACP” NCT00064259 ↗
Known as CDDP “METHODS: Forty (40) chemotherapy-naive patients with unresectable LAPC were randomly assigned (1:1) to either continuous fluorouracil (5-FU) 200 mg/m(2)/day (protracted IV) and...” PMID 21943032 ↗ Sep 2011
43

“The treatment regimen was as follows: oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (14-20 mg/m(2), on days 1 and 8) and 5-FU...” PMID 26734580 ↗ Oct 2015

“Cisplatin (cis-diammine dichloroplatinum (II), CDDP) is an inorganic platinum-based chemotherapeutic agent that is widely used in treatment of various solid malignancies as...” NCT05640817 ↗

“By far, the most common drug evaluated in HIPEC for EOC is Cisplatin. Cisplatin (CDDP) is a heavy metal complex containing a central atom of platinum surrounded by two chloride...” NCT03540017 ↗

“With the routine addition of systemic Cisplatin (CDDP) chemotherapy to local regional radiation, mortality from advanced cervical cancer in the United States is expected to...” NCT00257816 ↗

“Patients receive chemotherapy consisting of cisplatin (CDDP) via rapid intravenous infusion on day 1 followed by fluorouracil (5-FU) via 96-hour continuous infusion” NCT00002984 ↗

“patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1” NCT01670890 ↗

“The aim of this trial was to evaluate the safety and feasibility of moderate hypofractionated radiotherapy (HYP-RT) with concomitant cisplatin (CDDP).” PMID 30352576 ↗ Oct 2018

“concurrent FU plus cisplatin (CDDP), but did not significantly impact disease-free survival (DFS) or overall survival (OS) for anal canal carcinoma.” PMID 23150707 ↗ Nov 2012

“A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma” PMID 18417462 ↗ Apr 2008

“Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗

Show 33 more sources

Known as CIS “This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small...” NCT00599755 ↗
6

“Planned chemotherapy consisted of cisplatin (CIS) 50 mg/m2 days 1, 8 and vinorelbine (VIN) 25 mg/m2 days 1, 8, 15, 22 for four cycles.” PMID 15713522 ↗ Mar 2005

“Cisplatin (Cis) was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle.” NCT02393248 ↗

“gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car).” PMID 22031232 ↗ Jan 2012

“Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.” NCT00842712 ↗

“Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours.” NCT04402073 ↗

“cisplatin (Cis) chemotherapy” NCT05738057 ↗

Known as cis-diammine dichloroplatinum (II) “Cisplatin (cis-diammine dichloroplatinum (II), CDDP) is an inorganic platinum-based chemotherapeutic agent that is widely used in treatment of various solid malignancies as...” NCT05640817 ↗
1

“cisplatin (cis-diamminedichloroplatinum(II) (CDDP))” NCT07495098 ↗

Known as cis-diamminedichloroplatinum “Cisplatin is an alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.” NCT06783140 ↗
1

NCT04809103 ↗

Known as cis-dichlorodiamineplatin “Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug” NCT05039606 ↗
Known as cis-dichlorodiammineplatinums II “Cisplatin (cis-dichlorodiammineplatinums II) is a first generation platinum compound.” NCT04789941 ↗
Known as cis-platin: L01XA01 “cis-platin: L01XA01” NCT01614132 ↗
Known as cis-Platino “* cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)” NCT02371161 ↗
1

NCT00758381 ↗

Known as Cisplatin (C) “Cisplatin (C)” NCT01858922 ↗
Known as Cisplatin (CDDP) (Platinol) “Cisplatin (CDDP) (Platinol®)” NCT02128230 ↗
Known as Cisplatin (Platinol) “Cisplatin (Platinol®)” NCT02983045 ↗
3

“Cisplatin (Platinol)” NCT03415854 ↗

“Cisplatin (Platinol)” NCT04989218 ↗

“Cisplatin (Platinol)” NCT03138720 ↗

Known as Cisplatin (Platinol, Platinol-AQ) “Cisplatin (Platinol, Platinol-AQ)” NCT00659269 ↗
Known as Cisplatin - Cispulan “Cisplatin - Cispulan” NCT01096745 ↗
1

“Cisplatin ; Cispulan” NCT01834963 ↗

Known as cisplatin / cisplatinum “cisplatin / cisplatinum” NCT04268121 ↗
Known as Cisplatin 0.5mg/ml solution medac (Cisplatin) “Cisplatin 0.5mg/ml solution medac (Cisplatin)” NCT01320254 ↗
Known as Cisplatin for Injection “Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation” NCT06897579 ↗
1

“Cisplatin for Injection / Carboplatin Injection” NCT04568304 ↗

Known as Cisplatin Injection “Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four...” NCT06514027 ↗
1

“This study is to analyze the safety and efficacy of immunotherapy Triprilumab Injection combined with Gemcitabine Injection plus Cisplatin Injection in patients with advanced...” NCT04413734 ↗

Known as cisplatin liposomal “Patients receive cisplatin liposomal (SPI-77) IV over a minimum of 4 hours on day 1.” NCT00004083 ↗
1

NCT02702700 ↗

Known as Cisplatin, PLATINOL-AQ “Cisplatin, PLATINOL®-AQ” NCT00942838 ↗
Known as Cisplatin: CDDP “Cisplatin: CDDP” NCT00546130 ↗
Known as Cisplatin: Cisplatin for injection “Cisplatin: Cisplatin for injection” NCT02223611 ↗
Known as Cisplatine “Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %” NCT07128290 ↗
6

“CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.” NCT02014831 ↗

“Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1” NCT00535275 ↗

“R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)” NCT02858258 ↗

“1 cycle of Etoposide Cisplatine (EP) chemotherapy.” NCT05529251 ↗

NCT00137995 ↗

NCT00198354 ↗